Get the Stockscreener App
2.63
1.94%
0.05
Clene Inc stock is traded at $2.63, with a volume of 107.63K.
It is up +1.94% in the last 24 hours and down -12.33% over the past month.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
See More
Previous Close:
$2.58
Open:
$2.6
24h Volume:
107.63K
Relative Volume:
1.99
Market Cap:
$25.72M
Revenue:
$442.00K
Net Income/Loss:
$-30.46M
P/E Ratio:
-0.5897
EPS:
-4.46
Net Cash Flow:
$-27.47M
1W Performance:
-11.74%
1M Performance:
-12.33%
6M Performance:
-53.78%
1Y Performance:
-66.02%
1-Day Range:
$2.59
$2.8994
1-Week Range:
$2.55
$3.08
52-Week Range:
$2.55
$9.20
Clene Inc Stock (CLNN) Company Profile
Name
Clene Inc
Sector
Industry
Phone
801-676-9695
Address
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
2.63 | 25.72M | 442.00K | -30.46M | -27.47M | -4.46 |
|
KHC
Kraft Heinz Co
|
28.07 | 33.90B | 25.85B | 2.74B | 3.02B | 2.26 |
|
GIS
General Mills Inc
|
54.50 | 30.35B | 19.64B | 2.56B | 2.48B | 4.55 |
|
K
Kellanova
|
82.48 | 28.75B | 12.63B | 1.38B | 863.00M | 3.96 |
|
MKC
Mccormick Co Inc
|
76.07 | 20.39B | 6.68B | 792.60M | 774.40M | 2.94 |
|
HRL
Hormel Foods Corp
|
29.21 | 16.12B | 11.92B | 805.04M | 1.01B | 1.46 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-18-22 | Initiated | H.C. Wainwright | Buy |
| May-02-22 | Initiated | Canaccord Genuity | Buy |
| Sep-28-21 | Initiated | Oppenheimer | Outperform |
Clene Inc Stock (CLNN) Latest News
Benchmark Lowers Clene (NASDAQ:CLNN) Price Target to $33.00 - Defense World
D. Boral Capital Reaffirms Buy Rating for Clene (NASDAQ:CLNN) - Defense World
Clene Inc. Reports Reduced Losses Amid Strategic Cost-Saving Measures - TipRanks
Clene Inc. Advances CNM-Au8 Treatment for ALS, Reports Promising Q1 Results - citybuzz -
Clene Inc. Advances CNM-Au8 Toward Potential Accelerated Approval for ALS - citybuzz -
Clene’s Strategic Financial Management and Promising Clinical Developments Drive Buy Rating - TipRanks
Clene (CLNN) Maintains Buy Rating Despite Price Target Reduction | CLNN Stock News - GuruFocus
Clene (CLNN) Stock Rating and Price Target Maintained at Buy | CLNN Stock News - GuruFocus
Renaissance Technologies LLC Invests $96,000 in Clene Inc. (NASDAQ:CLNN) - Defense World
Clene Inc. to Showcase Neurodegenerative Research at D. Boral Capital Global Conference - citybuzz -
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Clene (CLNN) Reports Decline in Cash Reserves | CLNN Stock News - GuruFocus
Clene Faces Nasdaq Delisting Risk Amid Regulatory Pursuits - TipRanks
Clene (CLNN) Exceeds Revenue Expectations and Advances ALS Research | CLNN Stock News - GuruFocus
Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights - The Manila Times
Clene Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference | CLNN Stock News - GuruFocus
Clene Inc. SEC 10-Q Report - TradingView
Clene Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference - The Kingston Whig Standard
Geode Capital Management LLC Grows Stake in Clene Inc. (NASDAQ:CLNN) - Defense World
Clene Inc. expected to post a loss of 95 cents a shareEarnings Preview - TradingView
Clene Inc. Enters Agreement for $25M Equity Distribution By Investing.com - Investing.com Nigeria
Clene Inc. Enters Agreement for $25M Equity Distribution - Investing.com Australia
Clene Inc.Enters Equity Distribution Agreement With CanaccordSEC Filing - marketscreener.com
Analysts Set Clene Inc. (NASDAQ:CLNN) Target Price at $55.25 - Defense World
Clene (NASDAQ:CLNN) Research Coverage Started at Jones Trading - Defense World
Clene (CLNN) Receives Buy Rating and $30 Target from JonesResear - GuruFocus
Clene (CLNN) Receives Buy Rating and $30 Target from JonesResearch | CLNN Stock News - GuruFocus
Clene to Present at the Emerging Growth Conference | CLNN Stock News - GuruFocus
Nanomedicines Market to Witness Massive Growth by 2032 | Abbott - openPR.com
Clene to Present at the Emerging Growth Conference - The Manila Times
Clene’s (CLNN) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Nanomedicines Market Generated Opportunities, Future Scope 2025-2032 | Abbott, CombiMatrix, Clene Nanomedicine - newstrail.com
Clene’s (CLNN) Buy Rating Reiterated at HC Wainwright - Defense World
Clene reports MS patient improvements with CNM-Au8 treatment By Investing.com - Investing.com India
Clene announces evidence of remyelination, neuronal repair with CNM-Au8 - TipRanks
Clene reports MS patient improvements with CNM-Au8 treatment - Investing.com Australia
Clene (NASDAQ: CLNN) to Present at Jones Healthcare and Technology Innovation Conference - The Globe and Mail
CLNN stock touches 52-week low at $2.95 amid market challenges By Investing.com - Investing.com South Africa
CLNN stock touches 52-week low at $2.95 amid market challenges - Investing.com India
Clene to Present at the Jones Healthcare and Technology Innovation Conference - The Manila Times
Clene Reveals Latest ALS and MS Treatment Innovations at Major Healthcare Conference - Stock Titan
Promising Nanotechnology Stocks To ResearchMarch 29th - MarketBeat
Roth Capital Has Negative Estimate for Clene Q1 Earnings - Defense World
Clene Inc. settles debt with equity issuance - Investing.com
Clene Inc.'S (NASDAQ: CLNN) Q1 Virtual Investor Summit Presentation Available For On-Demand Viewing - MENAFN.COM
Roth Capital Has Optimistic Outlook of Clene FY2027 Earnings - Defense World
Research Analysts Issue Forecasts for Clene Q1 Earnings - Defense World
Clene (NASDAQ:CLNN) Earns Buy Rating from D. Boral Capital - The AM Reporter
What is HC Wainwright’s Estimate for Clene FY2028 Earnings? - Defense World
Clene stock touches 52-week low at $3.8 amid market challenges - Investing.com Australia
Clene stock touches 52-week low at $3.8 amid market challenges By Investing.com - Investing.com South Africa
Clene Inc Stock (CLNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Clene Inc Stock (CLNN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| General Resonance LLC | 10% Owner |
Mar 18 '25 |
Sale |
4.45 |
1,333 |
5,932 |
712,252 |
| MATLIN DAVID J | Director |
Sep 30 '24 |
Buy |
4.75 |
92,307 |
438,458 |
444,491 |
| Mortenson Mark | Chief Science Officer |
Sep 30 '24 |
Buy |
4.75 |
20,512 |
97,432 |
28,949 |
| Etherington Robert Dee | Chief Executive Officer |
Sep 30 '24 |
Buy |
4.75 |
10,000 |
47,500 |
40,149 |
| Etherington Robert Dee | Chief Executive Officer |
Jul 29 '24 |
Option Exercise |
3.00 |
27,320 |
81,960 |
30,149 |
1.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):